Skip to main content

Table 4 Characteristics of HBsAg positive IBD patients with altered transaminases

From: Prevalence of hepatitis B and clinical outcomes in inflammatory bowel disease patients in a viral-endemic region

Age

Sex

IBD

HBeAg

Highest ALT

Bilirubin at time of highest ALT

Albumin at time of highest ALT

HBV DNA level at time of altered transaminase

IBD medications

Possible cause of altered transaminase

Use of antiviral prophylaxis at time of altered transaminase

33

M

CD

-ve

176

17

40

4.21 log IU/mL

5ASA

Likely immune clearance phase with hepatitis B e-seroconversion

No

38

M

CD

+ve

146

14

38

7.85log IU/mL

Thiopurines, steroid

Possible hepatitis B reactivation vs azathioprine related liver dysfunction

No

53

M

UC

+ve

2520

55

32

7.07log IU/mL

5ASA, Steroid

Possible hepatitis B reactivation

No

46

M

CD

-ve

162

12

38

4.02log IU/mL

Thiopurines

Transient liver dysfunction with uncertain cause

No

32

F

UC

-ve

207

9

41

2.44log IU/mL

5ASA

Likely related to hyperemesis gravidum

No

36

F

CD

+ve

592

11

26

Undetectable

Thiopurines, Steroid, Biologics,

Possibly related to TPN; unlikely related to hepatitis B reactivation

Yes

  1. IBD inflammatory bowel disease, CD Crohn’s disease, UC ulcerative colitis, ALT Alanine Aminotransferase, HBV hepatitis B virus, HCC hepatocellular carcinoma, 5ASA 5-aminosalicylic acid